Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Change in Acquisitions & Divestments (2024 - 2025)

TScan Therapeutics (TCRX) has disclosed Change in Acquisitions & Divestments for 2 consecutive years, with $15.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Acquisitions & Divestments fell 80.14% to $15.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $201.2 million, a 4.46% increase, with the full-year FY2025 number at $201.2 million, up 4.46% from a year prior.
  • Change in Acquisitions & Divestments was $15.0 million for Q4 2025 at TScan Therapeutics, down from $34.0 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $76.2 million in Q2 2025 to a low of $15.0 million in Q4 2025.